Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
    Shannon, Alexander H.
    Manne, Ashish
    Diaz Pardo, Dayssy A.
    Pawlik, Timothy M.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [42] Immune checkpoint inhibitors for hepatocellular carcinoma
    Jensen, Christopher E.
    Loaiza-Bonilla, Arturo
    Bonilla-Reyes, Paula A.
    HEPATIC ONCOLOGY, 2016, 3 (03) : 201 - 211
  • [43] The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence
    Ruff, Samantha M.
    Pawlik, Timothy M.
    HEPATOMA RESEARCH, 2024, 10
  • [44] Gastrointestinal cancer treatment with immune checkpoint inhibitors
    Kim, Jin Won
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (05): : 342 - 348
  • [45] Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
    Ouyang, Tao
    Kan, Xuefeng
    Zheng, Chuansheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Han, Xinpu
    Sun, Qianhui
    Xu, Manman
    Zhu, Guanghui
    Gao, Ruike
    Ni, Baoyi
    Li, Jie
    SEMINARS IN LIVER DISEASE, 2023, 43 (04) : 383 - 401
  • [47] Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
    Zhang, Jin-Xing
    Chen, Pei
    Liu, Sheng
    Zu, Qing-Quan
    Shi, Hai-Bin
    Zhou, Chun-Gao
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 265 - 272
  • [48] Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle
    Sukowati, Caecilia
    Cabral, Loraine Kay D.
    Tiribelli, Claudio
    ANNALS OF HEPATOLOGY, 2022, 27 (05)
  • [49] The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma-A systematic review
    Meyers, Brandon M.
    Knox, Jennifer J.
    Liu, David M.
    McLeod, Deanna
    Ramjeesingh, Ravi
    Tam, Vincent C.
    Lim, Howard J.
    CANCER TREATMENT REVIEWS, 2023, 118
  • [50] Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials
    Gamboa, Adriana C.
    Kooby, David A.
    Maithel, Shishir K.
    Gamblin, T. Clark
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 129 (01) : 63 - 70